胡桃醌的抗肿瘤作用机制及靶向递送系统评价  

Evaluation of the Anti-Tumor Mechanism and Target Delivery System of Juglone

作　　者：陈亚娟 梁旭华 

机构地区：[1]商洛学院,生物医药与食品工程学院,陕西 商洛

出　　处：《药物资讯》2023年第3期209-216,共8页Pharmacy Information

摘　　要：胡桃醌是一种具有高活性的单体物质,对肿瘤细胞有一定的抑制作用,可使细胞DNA损坏、抑制转录、减少蛋白质水平以及诱导细胞死亡等,具有非常高的药用价值。但胡桃醌作为萘醌类化合物其自身仍具有多种缺陷,例如:水溶性低,稳定性较差,生物利用度低,并且具有一定的毒副作用,从而影响其在临床中的使用。由此大量实验研究企图将其与目前广泛应用于临床肿瘤和癌症治疗的药物载体技术相结合,研制胡桃醌纳米脂质载体,实现定点靶向给药、提高药物的治疗指数、减少药物的治疗剂量,尽可能的减少其在人体内的毒副作用,实现胡桃醌的临床应用。本文以最近的研究文献为参考,从胡桃醌的抗肿瘤机制、药物靶向递送系统研究、药物靶向递送系统安全性评价三个方面对胡桃醌进行系统的综述,指明其研究的可行性。Juglone is a highly active monolithic substance, which has a certain inhibitory effect on tumor cells. Juglone could make cell DNA damage, inhibit transcription, reduce protein levels and induce cell death, etc., and has very high medicinal value. However, as a carbide compound, Juglone still has a variety of defects, such as low water solubility, poor stability, low bio-utilization, and has certain toxic side effects, thus affecting the use of such substances in the clinic. Thus, a large number of experimental studies attempt to combine it with the drug carrier technology currently widely used in clinical tumor and cancer treatment, develop Juglone nanolipid carrier, realize its targeted drug administration, improve the therapeutic index of the drug, reduce the therapeutic dose of the drug, minimize its toxic side effects in the human body, and realize the clinical application of Juglone. This paper will take the recent research literature as a reference, from the anti-tumor mechanism of Juglone, drug-targeted delivery system research, drug-targeted delivery system safety evaluation of three aspects of Juglone to a systematic review, indicating the feasibility of its research.

关 键 词：胡桃醌 抗肿瘤 作用机制 靶向递送系统 

分 类 号：R28[医药卫生—中药学]